A study highlights an unmet need for patients with acute myeloid leukemia (AML) to access and afford genomic testing, especially among an older patient population. In a real-world setting of new and ...
The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...
Errata: Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint Analysis The classification of AML and therapeutic options are now largely driven ...
SAN DIEGO — A polygenic score can link outcomes in Black pediatric patients with acute myeloid leukemia (AML) to genetic traits that arise more frequently in this population, new data reveal. The ...
A small portion of adults in remission from a deadly blood cancer had persisting mutations that were detected, which predicted their risk of death from having the cancer return About 20,000 adults in ...
Amphista Therapeutics has reported preclinical leukemia data on its protein degrader, positioning the Big Pharma-partnered biotech to target a 2026 start date for a phase 1 clinical trial. The data, ...
Examining protein changes in peripheral blood cells just 24 hours after initiating chemotherapy for acute myeloid leukemia (AML) could predict 5-year overall survival, potentially allowing treatment ...
A recent study shows a regimen of low-dose homoharringtonine, cytarabine, and G-CSF (HAG) is an effective and promising treatment for pediatric patients with AML.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback